# Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

> **NCT05734066** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jazz Pharmaceuticals** · enrollment: 60 (estimated)

## Conditions studied

- Refractory Ewing Sarcoma
- Relapsed Ewing Sarcoma
- Ewing Sarcoma

## Interventions

- **DRUG:** Lurbinectedin

## Key facts

- **NCT ID:** NCT05734066
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-23
- **Primary completion:** 2028-01-28
- **Final completion:** 2028-04-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-03

## Collaborators

- Jazz Pharmaceuticals Ireland Limited

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05734066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05734066, "Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05734066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*